Developer docs
API playgroundTry for free, no card

Search company profiles

Polyganics

Full company profile

uuid0003xwv

Namestring
Polyganics
Legal namestring
Polyganics
Websiteurl
polyganics.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Polyganics is a Netherlands-based medical technology company, founded in 1999 and headquartered in Groningen, that develops, manufactures, and markets bioresorbable medical devices built on proprietary synthetic polymer chemistry. Its portfolio spans nerve repair, dural repair and closure, spine and orthopedics (including the RejuvaKnee™ regenerative meniscus implant), and dental regeneration products, designed as structural scaffolds that degrade as the body heals to enable permanent functional tissue restoration.

In 2022, Polyganics was acquired by Collagen Matrix, Inc., a 1997-founded pioneer in xenograft-based bioresorbable devices, which subsequently rebranded as Regenity Biosciences. The combined entity now operates from Paramus, NJ (HQ) and Allendale, NJ (new facility leased April 2026), with Polyganics functioning as the synthetic-polymer arm of a unified bioresorbable platform spanning collagen and polymer chemistry. The business monetizes through three streams: branded and private-label bioresorbable device sales (30M+ cumulative patients impacted), contract development and manufacturing (CDMO) services for medical device partners (5M+ devices produced annually, ISO 13485/MDSAP-certified and FDA-registered facilities), and collaborative/co-development licensing engagements leveraging a deep predicate device library. Notable commercial partnerships include GT Medical Technologies (GammaTile brain-tumor therapy, fast-tracked via 510(k)), with the combined enterprise supported by 170+ regulatory approvals worldwide and a distribution footprint in 80+ countries.

The company is privately held as a wholly-owned subsidiary of Regenity Biosciences, which is itself backed by private equity sponsors Linden Capital Partners (legacy investor) and Cinven (strategic investment, February 2026). It has 11–50 employees, sells through a hybrid direct enterprise sales motion and a global distributor/channel network, and does not publicly disclose pricing or revenue. Recent strategic activity is dominated by FDA 510(k) clearance and commercial launch of RejuvaKnee™, NMPA approval in China for dental products, the 2025 R&D 100 Award, the Cinven investment, and a new Allendale campus — all signaling an active commercial scaling phase.

Short descriptiontext

Polyganics, a Netherlands-based medical technology firm founded in 1999 and now part of Regenity Biosciences, develops proprietary synthetic polymer bioresorbable devices for nerve, dural, spine, orthopedic, and dental tissue regeneration, selling branded products and CDMO services to medical device OEMs across 80+ countries.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGroningen, Netherlands
HQ citystring
Groningen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioresorbable medical devices, regenerative medicine devices, contract medical device manufacturing, nerve repair devices, dental membrane products
Industry2 codes
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing3252
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Miscellaneous Plastics Products3080
  • Plastic Materials, Synth Resins & Nonvulcan Elastomers2821
Product category
Regenerative Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Private-label and branded product sales
TypeHardware Sales
Description

Sale of proprietary and white-label bioresorbable medical devices (nerve repair, dural repair, spine/orthopedics, dental) to medical device partners and distributors worldwide. 30M+ medical devices sold cumulatively.

regenity.com
2CDMO services revenue
TypeProfessional Services
Description

Contract development and manufacturing organization (CDMO) services — design, development, regulatory support, and precision manufacturing for partner companies developing regenerative therapies. Examples include support for GT Medical Technologies' GammaTile FDA submission.

regenity.com
3Collaborative/co-development licensing
TypeLicensing Royalties
Description

Customized collaborative product development engagements leveraging proprietary bioresorbable technology platforms and design asset library; partners co-create novel regenerative devices for rapid path-to-market.

regenity.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Polyganics develops, manufactures, and markets bioresorbable medical devices based on synthetic polymer chemistry for tissue regeneration across nerve repair, dural repair, spine/orthopedic, and dental applications. Following its 2022 acquisition by Collagen Matrix (now Regenity Biosciences), the portfolio also serves as the foundation for end-to-end Contract Development and Manufacturing Organization (CDMO) services delivered to medical device partners worldwide.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Polyganics was a leading medical technology company specializing in synthetic polymer bioresorbable devices and was acquired in 2022 by Collagen Matrix, Inc., which subsequently rebranded as Regenity Biosciences. Today, Polyganics' synthetic polymer portfolio sits alongside Regenity's legacy collagen (xenograft-based) offerings as part of a unified bioresorbable platform architecture. The combined offering is organized into therapeutic-area modules — Dental, Dural Repair & Closure, Spine & Orthopedics (including the RejuvaKnee™ meniscal repair device), and Nerve Repair — and is underpinned by proprietary Technology Platforms in collagen and synthetic polymer chemistry. Regenity also operates CDMO Services (Contract Development & Manufacturing), enabling partners to leverage the same bioresorbable expertise, design asset library, and FDA-registered, ISO 13485 / MDSAP-certified manufacturing infrastructure for private-label and co-developed regenerative medical devices. Notable highlights include 30+ million patients impacted, 170+ regulatory approvals worldwide, partners in 80+ countries, and 5M+ regenerative medical devices produced annually.

Product and service6 records
1RejuvaKnee™
CategoryRegenerative meniscus implant device
2Dental Product Portfolio
CategoryTherapeutic area — Dental
3Dural Repair & Closure Portfolio
CategoryTherapeutic area — Dural repair & closure
4Spine & Orthopedics Portfolio
CategoryTherapeutic area — Spine & orthopedics
5Nerve Repair Portfolio
CategoryTherapeutic area — Nerve repair
6CDMO Services
CategoryService offering — Contract Development & Manufacturing
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered with Regenity Biosciences (parent of Polyganics) to develop and manufacture GammaTile, a breakthrough in brain tumor treatment. Regenity's predicate technology enabled GT Medical Technologies to obtain 510(k) approval very quickly. Featured in 'Behind the Innovation' partner testimonial video series.

Strategic tierMinorTypeOthers
Description

Geistlich Bio-Gide® collagen membrane was used as the comparator in Regenity's multicenter clinical study for its novel crosslinked collagen membrane in China. Not a commercial partnership — referenced as a benchmark.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global orthopedics and medical devices leader with a large sports medicine franchise (relevant to RejuvaKnee™). Competes indirectly with Polyganics/Regenity in spine, orthopedics, and regenerative solutions at far greater scale.

TypeDirect peer
Description

UK-based regenerative medicine company developing bioresorbable scaffolds (dCELL®) for soft tissue repair including orthopedic and dental applications — directly comparable product modality to Polyganics' bioresorbable scaffolds.

TypeBroad incumbent
Description

Largest pure-play medical device company with spinal, cranial, neurological, and surgical franchises that overlap with Polyganics' dural repair, spine, and nerve repair portfolios. Operates as a broad incumbent with far greater scale.

TypeEmerging player
Description

Commercial-stage orthobiologics company focused on bone regeneration in spine surgery (i-FACTOR). Competes with Polyganics/Regenity in the spine regenerative category at a smaller, more specialized scale.

TypeDirect peer
Description

Non-profit tissue bank and regenerative medicine organization providing allograft and biologic devices plus CDMO-style services to medtech partners. Comparable to Polyganics/Regenity in regenerative CDMO services and tissue-repair product portfolio.

TypeBroad incumbent
Description

Global medical device company with sports medicine, orthopedics, and advanced wound management franchises — overlapping with Polyganics/Regenity's orthopedic, dental, and wound-care-adjacent regenerative portfolio.

TypeEmerging player
Description

US-focused regenerative medicine company marketing orthobiologic and spinal implant products. Comparable to Polyganics/Regenity in regenerative orthopedics/spine at a smaller scale and narrower geographic footprint.

TypeDirect peer
Description

Biomaterials business supplying bioresorbable polymers and regenerative materials to medical device manufacturers — directly comparable to Polyganics' synthetic polymer bioresorbable CDMO platform and a competitor for OEM material supply contracts.

TypeBroad incumbent
Description

Diversified medical device company with strong positions in neurosurgery (dural repair — direct overlap with Polyganics), regenerative technologies, and orthopedics. A broad incumbent offering overlapping capabilities in multiple Polyganics therapeutic areas.

TypeDirect peer
Description

Swiss-headquartered leader in collagen-based regenerative dental membranes (Bio-Gide®) and bone substitutes. Geistlich is the named comparator product in Polyganics/Regenity's China dental clinical study and directly competes in dental regeneration and orthobiologics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polyganics

Regenerative Medical Devicespolyganics.com

Polyganics, a Netherlands-based medical technology firm founded in 1999 and now part of Regenity Biosciences, develops proprietary synthetic polymer bioresorbable devices for nerve, dural, spine, orthopedic, and dental tissue regeneration, selling branded products and CDMO services to medical device OEMs across 80+ countries.

What Polyganics does

Polyganics is a Netherlands-based medical technology company, founded in 1999 and headquartered in Groningen, that develops, manufactures, and markets bioresorbable medical devices built on proprietary synthetic polymer chemistry. Its portfolio spans nerve repair, dural repair and closure, spine and orthopedics (including the RejuvaKnee™ regenerative meniscus implant), and dental regeneration products, designed as structural scaffolds that degrade as the body heals to enable permanent functional tissue restoration.

In 2022, Polyganics was acquired by Collagen Matrix, Inc., a 1997-founded pioneer in xenograft-based bioresorbable devices, which subsequently rebranded as Regenity Biosciences. The combined entity now operates from Paramus, NJ (HQ) and Allendale, NJ (new facility leased April 2026), with Polyganics functioning as the synthetic-polymer arm of a unified bioresorbable platform spanning collagen and polymer chemistry. The business monetizes through three streams: branded and private-label bioresorbable device sales (30M+ cumulative patients impacted), contract development and manufacturing (CDMO) services for medical device partners (5M+ devices produced annually, ISO 13485/MDSAP-certified and FDA-registered facilities), and collaborative/co-development licensing engagements leveraging a deep predicate device library. Notable commercial partnerships include GT Medical Technologies (GammaTile brain-tumor therapy, fast-tracked via 510(k)), with the combined enterprise supported by 170+ regulatory approvals worldwide and a distribution footprint in 80+ countries.

The company is privately held as a wholly-owned subsidiary of Regenity Biosciences, which is itself backed by private equity sponsors Linden Capital Partners (legacy investor) and Cinven (strategic investment, February 2026). It has 11–50 employees, sells through a hybrid direct enterprise sales motion and a global distributor/channel network, and does not publicly disclose pricing or revenue. Recent strategic activity is dominated by FDA 510(k) clearance and commercial launch of RejuvaKnee™, NMPA approval in China for dental products, the 2025 R&D 100 Award, the Cinven investment, and a new Allendale campus — all signaling an active commercial scaling phase.

Polyganics firmographics

Firmographics
Name
Polyganics
Legal name
Polyganics
Website
https://polyganics.com
Company type
Private
Founded year
1997
Operating status
Acquired
Headcount range
11–50 employees
Short description
Polyganics, a Netherlands-based medical technology firm founded in 1999 and now part of Regenity Biosciences, develops proprietary synthetic polymer bioresorbable devices for nerve, dural, spine, orthopedic, and dental tissue regeneration, selling branded products and CDMO services to medical device OEMs across 80+ countries.
Ownership category
akta.pro rank

Polyganics industry classification

Industry
Product category
Regenerative Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Miscellaneous Plastics Products (3080), Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)
akta.pro industry
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Bioresorbable medical devices
  • Regenerative medicine devices
  • Contract medical device manufacturing
  • Nerve repair devices
  • Dental membrane products

Where Polyganics is headquartered

Location

Headquarters

HQ city
Groningen
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Polyganics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Private-label and branded product sales: Sale of proprietary and white-label bioresorbable medical devices (nerve repair, dural repair, spine/orthopedics, dental) to medical device partners and distributors worldwide. 30M+ medical devices sold cumulatively.
  2. CDMO services revenue: Contract development and manufacturing organization (CDMO) services — design, development, regulatory support, and precision manufacturing for partner companies developing regenerative therapies. Examples include support for GT Medical Technologies' GammaTile FDA submission.
  3. Collaborative/co-development licensing: Customized collaborative product development engagements leveraging proprietary bioresorbable technology platforms and design asset library; partners co-create novel regenerative devices for rapid path-to-market.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Polyganics product offering

Product offering

Core offering

Polyganics develops, manufactures, and markets bioresorbable medical devices based on synthetic polymer chemistry for tissue regeneration across nerve repair, dural repair, spine/orthopedic, and dental applications. Following its 2022 acquisition by Collagen Matrix (now Regenity Biosciences), the portfolio also serves as the foundation for end-to-end Contract Development and Manufacturing Organization (CDMO) services delivered to medical device partners worldwide.

Product overview

Polyganics was a leading medical technology company specializing in synthetic polymer bioresorbable devices and was acquired in 2022 by Collagen Matrix, Inc., which subsequently rebranded as Regenity Biosciences. Today, Polyganics' synthetic polymer portfolio sits alongside Regenity's legacy collagen (xenograft-based) offerings as part of a unified bioresorbable platform architecture. The combined offering is organized into therapeutic-area modules — Dental, Dural Repair & Closure, Spine & Orthopedics (including the RejuvaKnee™ meniscal repair device), and Nerve Repair — and is underpinned by proprietary Technology Platforms in collagen and synthetic polymer chemistry. Regenity also operates CDMO Services (Contract Development & Manufacturing), enabling partners to leverage the same bioresorbable expertise, design asset library, and FDA-registered, ISO 13485 / MDSAP-certified manufacturing infrastructure for private-label and co-developed regenerative medical devices. Notable highlights include 30+ million patients impacted, 170+ regulatory approvals worldwide, partners in 80+ countries, and 5M+ regenerative medical devices produced annually.

Differentiator

Problem solved

Functional benefit

Products and services

  • RejuvaKnee™
  • Dental Product Portfolio
  • Dural Repair & Closure Portfolio
  • Spine & Orthopedics Portfolio
  • Nerve Repair Portfolio
  • CDMO Services

Companies that use Polyganics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Polyganics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Polyganics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • GT Medical TechnologiescoreStrategic or Co-development PartnerPartnered with Regenity Biosciences (parent of Polyganics) to develop and manufacture GammaTile, a breakthrough in brain tumor treatment. Regenity's predicate technology enabled GT Medical Technologies to obtain 510(k) approval very quickly. Featured in 'Behind the Innovation' partner testimonial video series.
  • Geistlich (reference comparator)minorOthersGeistlich Bio-Gide® collagen membrane was used as the comparator in Regenity's multicenter clinical study for its novel crosslinked collagen membrane in China. Not a commercial partnership — referenced as a benchmark.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Polyganics competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Global orthopedics and medical devices leader with a large sports medicine franchise (relevant to RejuvaKnee™). Competes indirectly with Polyganics/Regenity in spine, orthopedics, and regenerative solutions at far greater scale.
  • Medtronic: Largest pure-play medical device company with spinal, cranial, neurological, and surgical franchises that overlap with Polyganics' dural repair, spine, and nerve repair portfolios. Operates as a broad incumbent with far greater scale.
  • Smith+Nephew: Global medical device company with sports medicine, orthopedics, and advanced wound management franchises — overlapping with Polyganics/Regenity's orthopedic, dental, and wound-care-adjacent regenerative portfolio.
  • Integra LifeSciences: Diversified medical device company with strong positions in neurosurgery (dural repair — direct overlap with Polyganics), regenerative technologies, and orthopedics. A broad incumbent offering overlapping capabilities in multiple Polyganics therapeutic areas.

Direct peers

  • Tissue Regenix Group: UK-based regenerative medicine company developing bioresorbable scaffolds (dCELL®) for soft tissue repair including orthopedic and dental applications — directly comparable product modality to Polyganics' bioresorbable scaffolds.
  • MTF Biologics: Non-profit tissue bank and regenerative medicine organization providing allograft and biologic devices plus CDMO-style services to medtech partners. Comparable to Polyganics/Regenity in regenerative CDMO services and tissue-repair product portfolio.
  • DSM Biomedical (dsm-firmenich): Biomaterials business supplying bioresorbable polymers and regenerative materials to medical device manufacturers — directly comparable to Polyganics' synthetic polymer bioresorbable CDMO platform and a competitor for OEM material supply contracts.
  • Geistlich Pharma: Swiss-headquartered leader in collagen-based regenerative dental membranes (Bio-Gide®) and bone substitutes. Geistlich is the named comparator product in Polyganics/Regenity's China dental clinical study and directly competes in dental regeneration and orthobiologics.

Emerging players

  • Cerapedics: Commercial-stage orthobiologics company focused on bone regeneration in spine surgery (i-FACTOR). Competes with Polyganics/Regenity in the spine regenerative category at a smaller, more specialized scale.
  • Xtant Medical: US-focused regenerative medicine company marketing orthobiologic and spinal implant products. Comparable to Polyganics/Regenity in regenerative orthopedics/spine at a smaller scale and narrower geographic footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Polyganics social profiles

Digital presence

Polyganics compliance and trust

Trust signal

Compliance3 records

Polyganics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polyganics leadership team

Management profile

Number of profiles

Profiles5 records

Polyganics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polyganics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyganics

What does Polyganics do?

Polyganics develops, manufactures, and markets bioresorbable medical devices based on synthetic polymer chemistry for tissue regeneration across nerve repair, dural repair, spine/orthopedic, and dental applications. Following its 2022 acquisition by Collagen Matrix (now Regenity Biosciences), the portfolio also serves as the foundation for end-to-end Contract Development and Manufacturing Organization (CDMO) services delivered to medical device partners worldwide.

Is Polyganics a public or private company?

Polyganics is a private company. It is classified as private equity controlled and is currently acquired.

When was Polyganics founded?

Polyganics was founded in 1997. It employs 11 to 50 people.

Where is Polyganics based?

Polyganics is headquartered in Groningen, Netherlands, in the Europe region.

How does Polyganics make money?

Three revenue lines are on record. Private-label and branded product sales are the primary driver. The others are CDMO services revenue and collaborative/co-development licensing.

Who are Polyganics's main competitors?

Broad incumbents on record are Stryker, Medtronic, Smith+Nephew and Integra LifeSciences. Direct peers are Tissue Regenix Group, MTF Biologics, DSM Biomedical (dsm-firmenich) and Geistlich Pharma. Emerging players are Cerapedics and Xtant Medical.

Does Polyganics have an API?

No public API is recorded for Polyganics.

What industry is Polyganics in?

Polyganics's product category is Regenerative Medical Devices. Its primary akta.pro industry code is HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO, with a secondary code of HLAGABAD, Cell Therapy CDMO. Its NAICS code is 339112 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals